Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/18/2009

    NOVATO, Calif., Feb. 18 /PRNewswire-FirstCall/ --

    Financial Highlights ($ in millions, except per share data)

    Item                         FY 2008           FY 2007 Comparison
    Total BioMarin Revenue        $296.5            143.9% increase
    Naglazyme Net Product
     Revenue                      $132.7            53.9% increase
    Aldurazyme Net Sales by
     Genzyme                      $151.3            22.3% increase
    Aldurazyme BioMarin Net
     Product Revenue              $72.5             NA
    Kuvan Net Product Revenue     $46.7             $0.4
    GAAP Net Income (Loss)        $30.8             ($15.8)
    GAAP Net Income (Loss)
     per share                    $0.31 (basic),   ($0.16) (basic and diluted)
                                  $0.29 (diluted)
    Non-GAAP Net Income (Loss)    $56.1             $2.5
    Non-GAAP Net Income (Loss)
     per share                    $0.57 (basic),    $0.03 (basic and diluted)
                                  $0.52 (diluted)


BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced financial results for the fourth quarter and year ended December 31, 2008. Net income was $24.5 million ($0.21 per fully diluted share) for the fourth quarter of 2008, compared to net income of $2.6 million ($0.03 per fully diluted share) for the fourth quarter of 2007. Non-GAAP net income was $31.9 million ($0.27 per fully diluted share) for the fourth quarter of 2008, compared to non-GAAP net income of $8.1 million ($0.08 per fully diluted share) for the fourth quarter of 2007. Non-GAAP net income/loss excludes non-cash stock compensation expense, which was $7.4 million for the three months ended December 31, 2008 and $5.5 million for the three months ended December 31, 2007.

Net income for the year ended December 31, 2008 was $30.8 mill
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
2. BioMarin to Present at the Piper Jaffray Healthcare Conference
3. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
4. BioMarin to Present at the Credit Suisse Healthcare Conference
5. BioMarin Announces Third Quarter 2008 Financial Results
6. BioMarin Corrects Information Included in Bloomberg Article
7. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Citi Biotech Day
10. BioMarin Announces Roll-Out of National PKU Registry
11. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... NEW YORK , Oct. 24, ... formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company ... has implemented a 1-for-50 reverse split of its ... on Friday, October 24, 2014. PlasmaTech,s common stock ... CUSIP number 72754H109 and temporary ticker symbol "ACCPD". ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... 14, 2011 Elsevier, a world-leading provider ... and the Federation of Biochemical Societies (FEBS) announced today ... open access journal. The journal is dedicated to publishing ... both health and disease. , ,In launching this new ...
... CEO of Arteriocyte Cellular Therapies Medical Systems (Arteriocyte) and ... are combining efforts to raise awareness of opportunities for ... They will inspire, celebrate and encourage women to choose ... thrive in STEM fields at a breakfast to be ...
... Amgen (NASDAQ: AMGN ) today announced ... studies were presented at the 53rd Annual Meeting and Exposition ... 2011, in San Diego. Of note, final results from the ... safety and efficacy of Nplate in adults with primary ...
Cached Biology Technology:Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio 2Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio 3Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields 2Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 2Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 3Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 4Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 5Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 6Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 7Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 8Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim) 9
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/17/2014)... in German . ... drugs. When treating overdoses, doctors are often limited to supportive ... there is a combination of drugs involved. So what can ... his grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute ... answer to this question. "The task was to develop an ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2
... Institute for Medical Research today unveiled a collaboration with ... (MIT) being spearheaded by GlaxoSmithKline (GSK), which aims to ... body,s organs and functions. This initiative is discussed in ... is a powerful collaboration between leaders in the field ...
... from turtles, and scientists who have just sequenced the first ... the shelled creatures, remarkable longevity and ability to survive for ... turtles use to protect their heart and brain from oxygen ... stroke, the researchers said. UCLA conservation biologist ...
... April 9, 2013 Many terrestrial animals are frequently observed ... a lion kill in the Serengeti or a buzzard swooping ... activity in the oceans is especially difficult, and often overlooked ... published in PLOS ONE titled, " White sharks ...
Cached Biology News:Feinstein Institute collaborates with GSK, UPenn, MIT to research body's electrical impulses 2Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 2Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 3Great white sharks 2
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
... Mutation Explorer processes up to 48 lanes, ... Data input can be from either slab ... or primer chemistries. The detection parameters in ... to analyst consistency. We have built ...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: